NN Investment Partners Holdings N.V. Has $11.38 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

NN Investment Partners Holdings N.V. increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 3.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,488 shares of the medical research company’s stock after purchasing an additional 1,704 shares during the period. NN Investment Partners Holdings N.V.’s holdings in IQVIA were worth $11,375,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Perennial Advisors LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at $27,000. Allworth Financial LP boosted its holdings in IQVIA by 72.6% in the third quarter. Allworth Financial LP now owns 126 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 53 shares during the last quarter. RE Advisers Corp increased its position in IQVIA by 53.3% in the third quarter. RE Advisers Corp now owns 141 shares of the medical research company’s stock worth $34,000 after purchasing an additional 49 shares during the period. Toth Financial Advisory Corp bought a new stake in IQVIA during the 3rd quarter worth about $54,000. Finally, Ellevest Inc. lifted its position in IQVIA by 21.7% during the 3rd quarter. Ellevest Inc. now owns 247 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 44 shares during the period. 86.53% of the stock is currently owned by hedge funds and other institutional investors.

IQV has been the subject of a number of recent research reports. Evercore ISI reissued an “outperform” rating on shares of IQVIA in a research note on Friday, November 12th. Jefferies Financial Group upped their target price on shares of IQVIA from $300.00 to $309.00 and gave the company a “buy” rating in a research report on Wednesday, November 17th. Piper Sandler raised their price target on IQVIA from $250.00 to $261.00 and gave the stock a “neutral” rating in a research report on Thursday, November 18th. Deutsche Bank Aktiengesellschaft upped their price objective on IQVIA from $250.00 to $282.00 and gave the company a “buy” rating in a report on Wednesday, October 27th. Finally, Morgan Stanley raised their target price on IQVIA from $280.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, October 22nd. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $279.35.

In related news, Director John G. Danhakl bought 10,000 shares of IQVIA stock in a transaction on Wednesday, December 22nd. The stock was acquired at an average price of $272.93 per share, with a total value of $2,729,300.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Connaughton sold 555,094 shares of IQVIA stock in a transaction dated Monday, November 29th. The shares were sold at an average price of $262.60, for a total value of $145,767,684.40. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.

Shares of IQV opened at $247.34 on Friday. The stock has a market capitalization of $47.25 billion, a price-to-earnings ratio of 62.78, a PEG ratio of 1.66 and a beta of 1.41. The company has a debt-to-equity ratio of 2.07, a quick ratio of 0.94 and a current ratio of 0.94. IQVIA Holdings Inc. has a 52 week low of $170.00 and a 52 week high of $285.61. The stock has a fifty day moving average of $265.44 and a 200-day moving average of $256.26.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, October 21st. The medical research company reported $2.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.05. IQVIA had a return on equity of 25.91% and a net margin of 5.67%. The business had revenue of $3.39 billion for the quarter, compared to analyst estimates of $3.35 billion. During the same quarter in the prior year, the company earned $1.50 earnings per share. The company’s quarterly revenue was up 21.7% on a year-over-year basis. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 8.21 EPS for the current year.

About IQVIA

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions segment provides mission critical information, technology solutions and real world solutions and services to the firm’s life science clients.

See Also: Momentum Indicators

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.